Overall Survival | Progression-free Survival | |||||
---|---|---|---|---|---|---|
Covariates | P value logrank | P value cox | HR, 95%CI cox | P value logrank | P value cox | HR, 95%CI cox |
Age at PM | ||||||
≥18 (n = 26) | 0.615 | 0.620 | 1.279, 0.483–3.387 | 0.208 | 0.228 | 0.604, 0.267–1.37 |
< 18 (n = 12) | ||||||
Gender | ||||||
Male (n = 27) | 0.671 | 0.675 | 0.81, 0.303–2.167 | 0.753 | 0.761 | 0.884, 0.399–1.958 |
Female (n = 11) | ||||||
Timing | ||||||
Synchronous (n = 12) | 0.381 | 0.390 | 1.544, 0.574–4.153 | 0.123 | 0.14 | 1.859, 0.817–4.232 |
Metachronous (n = 25) | ||||||
Progression under CHT | ||||||
No (n = 12) | 0.003 | 0.011 | 0.129, 0.027–0.622 | 0.050 | 0.071 | 0.404, 0.15–1.082 |
Yes (n = 10) | ||||||
Surgical approach | ||||||
Thoracotomy (n = 36) | 0.272 | 0.478 | 22.451, 0.004–122,339.634 | 0.524 | 0.546 | 1.853, 0.251–13.692 |
VATS (n = 2) | ||||||
Metastases size | ||||||
> 15 mm (n = 14) | 0.339 | 0.351 | 0.627, 0.235–1.674 | 0.725 | 0.734 | 1.145, 0.524–2.505 |
≤15 (n = 20) | ||||||
LN resected | ||||||
Yes (n = 20) | 0.134 | 0.148 | 0.472, 0.171–1.306 | 0.104 | 0.121 | 0.536, 0.244–1.178 |
No (n = 16) | ||||||
LN positive | ||||||
Yes (n = 1) | < 0.001 | N/A | N/A | 0.072 | 0.130 | 0.174, 0.018–1.673 |
No (n = 19) | ||||||
G | ||||||
2,3 (n = 36) | 0.6 | 0.606 | 1.474, 0.336–6.471 | 0.952 | 0.954 | 0.958, 0.226–4.059 |
1 (n = 2) | ||||||
N° of Metastases | ||||||
≤3 (n = 20) | 0.002 | 0.005 | 0.242, 0.089–0.64 | 0.001 | 0.003 | 0.291, 0.130–0.651 |
> 3 (n = 16) | ||||||
Repeat PM | ||||||
Yes (n = 19) | 0.573 | 0.579 | 0.766, 0.3–1.961 | 0.226 | 0.246 | 0.636, 0.297–1.366 |
No (n = 19) | ||||||
Unilateral/Bilateral PM | ||||||
Unilateral (n = 19) | 0.517 | 0.523 | 0.744, 0.3–1.842 | 0.434 | 0.451 | 0.753, 0.36–1.573 |
Bilateral (n = 19) | ||||||
Histology (CS = 5, OST = 20, ES = 13) | 0.184 | 0.824 | 1.09, 0.513–2.315 | 0.428 | 0.845 | 1.061, 0.587–1.915 |